Viewing nowCombinationSitagliptin-Metformin Duo 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
TDS Pharm Co., Ltd.

MFDS item code 202300840 · Approved 2023.03.13 · Insurance code 679802210
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used to help control blood sugar levels in patients with type 2 diabetes who are also following a diet and exercise regimen. Sitagliptin and Metformin work together to effectively lower blood sugar levels. Regular use can significantly assist in blood sugar management and improve health status.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who do not achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current dose of metformin. - Patients switching from concomitant sitagliptin and metformin therapy to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with concomitant metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should be based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medicine is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in the treatment regimen for type 2 diabetes may cause changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this medicine should not be initiated because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin and is used for diabetes treatment. First, serious allergic reactions may occur while taking this medication, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear, immediately stop use and consult a doctor. Additionally, there is a risk of acute pancreatitis, which is inflammation of the pancreas, so if symptoms such as abdominal pain, vomiting, or severe abdominal discomfort arise, inform medical personnel immediately. The metformin component in this drug can cause a rare but life-threatening side effect called lactic acidosis, so seek immediate treatment if symptoms such as shortness of breath, muscle pain, fatigue, or abdominal pain occur. Patients with poor kidney function, dehydration, severe infection, heart disease, or liver disease should avoid taking this medication for safety reasons. It is advisable to temporarily discontinue this medication before and after examinations using iodine contrast media and to resume only after confirming normal kidney function. Pregnant women, women who may become pregnant, and breastfeeding women should not take this medication. This drug should be administered with caution to patients with irregular meals, intense exercise, or a history of certain allergies. There may be side effects such as diarrhea, nausea, vomiting, headache, and upper respiratory infections during the course of treatment, so if symptoms are severe, consult a doctor. When taken with other blood sugar-lowering medications or insulin, the risk of hypoglycemia may increase, so blood sugar levels should be monitored frequently, and medication dosage adjusted if necessary. During treatment, regular checks of kidney function, blood tests, and vitamin B12 levels should be performed to ensure there are no abnormalities. Alcohol consumption can increase the risk of lactic acidosis, so it is important not to drink excessively while taking this drug. If surgery is planned, discontinue this medication 48 hours before the procedure and only resume after confirming that kidney function has returned to normal afterwards. Lastly, this medication is not advised for children under 18 years or those under 10 years of age as safety and efficacy have not been established.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is best kept at room temperature between 1 degree and 30 degrees Celsius. By storing it this way, the efficacy of the medication can be well maintained.
Bright pink oval film-coated tablet
Bottle - 100 tablets/bottle, Bottle - 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.69mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
TDS Pharm Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.